NCT06566391 2024-08-22
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
Phase 2 Unknown
Clinical Trials
83 trialsNCT04062656 2024-03-12
IMAGINE
University Hospital, Essen
Phase 2 Unknown
NCT03818685 2024-02-12
BreastImmune03
Centre Leon Berard
Phase 2 Unknown
NCT06235164 2024-01-31
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Fujian Medical University
Unknown
NCT03146650 2024-01-18
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
Northwestern University
Phase 2 Unknown
NCT06204614 2024-01-12
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Unknown
NCT05859477 2024-01-02
NIVOFGFR2
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT03638375 2023-12-12
ACTME
Leiden University Medical Center
Phase 1/2 Unknown
NCT02977052 2023-11-15
OpACIN-neo
The Netherlands Cancer Institute
Phase 2 Unknown
NCT03458455 2023-11-01
TREATMENT
Oslo University Hospital
Unknown
NCT03097939 2023-10-11
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
National Cancer Centre, Singapore
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05418660 2023-09-18
I-STOP
University of Milano Bicocca
Unknown
NCT04741438 2023-08-30
RAR-Immune
Centre Leon Berard
Phase 3 Unknown
NCT03313544 2023-04-21
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
Assistance Publique Hopitaux De Marseille
Phase 4 Unknown
NCT04981899 2023-04-12
NICE-40
St. Petersburg State Pavlov Medical University
Phase 1/2 Unknown
NCT03528408 2023-04-11
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Hoosier Cancer Research Network
Phase 2 Unknown
NCT05772624 2023-03-16
Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05175235 2023-03-03
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
National University Hospital, Singapore
Phase 1/2 Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT04359199 2023-02-10
QUASAR
University of California, San Diego
Unknown
NCT03995017 2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2 Unknown
NCT04612530 2022-12-20
PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
Amsterdam UMC, location VUmc
Phase 1 Unknown
NCT03682276 2022-12-13
PRIME-HCC
Imperial College London
Phase 1/2 Unknown
NCT03879122 2022-10-26
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Spanish Oncology Genito-Urinary Group
Phase 2/3 Unknown
NCT03529890 2022-10-20
RACE IT
Technical University of Munich
Phase 2 Unknown
NCT05588297 2022-10-20
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT03825367 2022-10-12
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Unknown
NCT03542461 2022-10-03
EDEN
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Unknown
NCT04913025 2022-09-21
REFINE
University College, London
Phase 2 Unknown
NCT04575922 2022-09-08
Nivolumab+Ipilimumab+RT in MSS mCRC
Massachusetts General Hospital
Phase 2 Unknown
NCT04525638 2022-08-02
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
Phase 2 Unknown
NCT05265650 2022-07-19
Noelia
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1/2 Unknown
NCT05461235 2022-07-18
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
China Medical University, China
Phase 2 Unknown
NCT05213312 2022-06-15
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT03374839 2022-05-06
Nivo-TIL
Nantes University Hospital
Phase 1/2 Unknown
NCT03161756 2022-04-07
CHARLI
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Unknown
NCT04876313 2022-04-06
NURE-Combo
IRCCS San Raffaele
Phase 2 Unknown
NCT05236608 2022-03-25
ADIVO Lung
National University Hospital, Singapore
Phase 1/2 Unknown
NCT03993249 2022-03-23
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy
Hellenic GenitoUrinary Cancer Group
Phase 2 Unknown
NCT02499367 2022-03-22
TONIC
The Netherlands Cancer Institute
Phase 2 Unknown
NCT05281926 2022-03-16
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
National Taiwan University Hospital
Phase 1 Unknown
NCT05162118 2022-03-09
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
Zhejiang University
Phase 1/2 Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05224999 2022-02-04
Nivolumab for Recurrent/Metastatic Carcinosarcoma
Yonsei University
Phase 2 Unknown
NCT04233840 2022-01-27
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 1/2 Unknown
NCT04620954 2021-12-01
ORION-02
National Cancer Centre, Singapore
Phase 1/2 Unknown
NCT03219775 2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2 Unknown